Literature DB >> 15518824

Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.

Annemarie N Lekkerkerker1, Irene S Ludwig, Sandra J van Vliet, Yvette van Kooyk, Teunis B H Geijtenbeek.   

Abstract

The interaction of DC-SIGN with gp120 provides an attractive target for intervention of HIV-1 transmission. Here, we have investigated the potency of gp120 antibodies to inhibit the DC-SIGN-gp120 interaction. We demonstrate that although the V3 loop is not essential for DC-SIGN binding, antibodies against the V3 loop partially inhibit DC-SIGN binding, suggesting that these antibodies sterically hinder DC-SIGN binding to gp120. Polyclonal antibodies raised against non-glycosylated gp120 inhibited both low and high avidity DC-SIGN-gp120 interactions in contrast to polyclonal antibodies raised against glycosylated gp120. Thus, glycans present on gp120 may prevent the generation of antibodies that block the DC-SIGN-gp120 interactions. Moreover, the polyclonal antibodies against non-glycosylated gp120 efficiently inhibited HIV-1 capture by both DC-SIGN transfectants and immature dendritic cells. Therefore, non-glycosylated gp120 may be an attractive immunogen to elicit gp120 antibodies that block the binding to DC-SIGN. Furthermore, we demonstrate that DC-SIGN binding to gp120 enhanced CD4 binding, suggesting that DC-SIGN induces conformational changes in gp120, which may provide new targets for neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15518824     DOI: 10.1016/j.virol.2004.08.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.

Authors:  Thuong H Tran; Rasha El Baz; Andrea Cuconati; James Arthos; Pooja Jain; Zafar K Khan
Journal:  J Antivir Antiretrovir       Date:  2011-10-17

2.  Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Authors:  William Dowling; Elizabeth Thompson; Catherine Badger; Jenny L Mellquist; Aura R Garrison; Jeffery M Smith; Jason Paragas; Robert J Hogan; Connie Schmaljohn
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

3.  Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins.

Authors:  Mary Requena; Hicham Bouhlal; Nadine Nasreddine; Hela Saidi; Jean-Chrysostome Gody; Sylvie Aubry; Gérard Grésenguet; Michel D Kazatchkine; Rafick-Pierre Sekaly; Laurent Bélec; Hakim Hocini
Journal:  Immunology       Date:  2007-11-10       Impact factor: 7.397

4.  DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.

Authors:  Karolin Hijazi; Yufei Wang; Carlo Scala; Simon Jeffs; Colin Longstaff; Daniel Stieh; Beth Haggarty; Guido Vanham; Dominique Schols; Jan Balzarini; Ian M Jones; James Hoxie; Robin Shattock; Charles G Kelly
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

5.  Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes.

Authors:  Marloes A Naarding; Elly Baan; Georgios Pollakis; William A Paxton
Journal:  Retrovirology       Date:  2007-01-30       Impact factor: 4.602

6.  Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.

Authors:  James M Binley; Stacie Ngo-Abdalla; Penny Moore; Michael Bobardt; Udayan Chatterji; Philippe Gallay; Dennis R Burton; Ian A Wilson; John H Elder; Aymeric de Parseval
Journal:  Retrovirology       Date:  2006-07-03       Impact factor: 4.602

7.  Synthesis of fluorescence labelled aptamers for use as low-cost reagents in HIV/AIDS research and diagnostics.

Authors:  Kanyane Malatji; Pascaline N Fru; Hazel Mufhandu; Kabamba Alexandre
Journal:  Biomed Rep       Date:  2021-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.